Concert Pharma GAAP EPS of -$0.58 beats by $0.01, revenue of $0.08M in-line

Nov. 07, 2022 7:12 AM ETConcert Pharmaceuticals, Inc. (CNCE)By: Deepa Sarvaiya, SA News Editor
  • Concert Pharma press release (NASDAQ:CNCE): Q3 GAAP EPS of -$0.58 beats by $0.01.
  • Revenue of $0.08M (-84.0% Y/Y) in-line.
  • Cash, cash equivalents and investments as of September 30, 2022 totaled $148.9 million, compared to $141.6 million as of December 31, 2021. Under its current operating plan, the Company expects its cash, cash equivalents and investments to fund the Company through the second quarter of 2023.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.